Fyn kinase in brain diseases and cancer: the search for inhibitors

S Schenone1, C Brullo, F Musumeci

  • 1Dipartimento di Scienze Farmaceutiche, Università degli Studi di Genova, Viale Benedetto XV, 3, I-16132, Genova, Italy. schensil@unige.it

Insights

Fyn kinase is implicated in brain diseases and cancer. This review highlights small molecule inhibitors targeting Fyn, offering potential therapeutic strategies for neurodegenerative conditions and malignancies.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Neuroscience

Background:

  • Fyn is a non-receptor tyrosine kinase in the Src family.
  • It plays roles in neuronal functions (myelination, oligodendrocyte formation) and inflammation.
  • Fyn is linked to Alzheimer's, Parkinson's diseases, and upregulated in malignancies.

Purpose of the Study:

  • To review small molecule tyrosine kinase inhibitors targeting Fyn.
  • To provide a starting point for researchers investigating Fyn inhibition.

Main Methods:

  • Literature review of experimental studies.
  • Analysis of enzymatic and cell-based assays for Fyn inhibition.

Main Results:

  • No specific Fyn inhibitors are currently available.
  • Some compounds inhibit other Src family kinases or different tyrosine kinases.
  • Multitargeted inhibitors show therapeutic potential for cancer and neurodegenerative diseases.

Conclusions:

  • Fyn inhibition is a promising therapeutic strategy.
  • Small molecule inhibitors targeting Fyn, even non-selective ones, warrant further investigation.
  • This review compiles relevant inhibitors for future research.